| Objectives:To observe the effect of endothelin-1(ET-1) on the cell growth, the adhesion, migration and the content of intercellular adhesion molecule-1( ICAM-1) of A375 human melanoma cells,to study the mechanism of ET-1 in treating vitiligo.Methods:To treat A375 human melanoma cells in different concentration of ET-1,to observe the growth of A375 human melanoma cells by MTT,the abilities of adhesion and migration were detected by the methods of transwell migration and adherence assays, the content of ICAM-1 of A375 human melanoma cells by flow cytometry.Results:1.When the concentration of ET-1 was between 0.002~0.2ug/ml, it showed an increasing tendency of the amount of A375 human melanoma cells with the concentration of ET-1 raised.When the concentration of ET-1 was at 2ug/ml, the amount of A375 human melanoma cells decreased,the growth of the cells was inhibited.Compared with the control,when the concentration of ET-1 was at 0.2ug/ml,the proliferation of the cells was the most obviousliest(P<0.01).2.When the concentration of ET-1 was between 0.002~0.2ug/ml,it could promote the adhesion to fibronection and the migration into micropore filter membranes with the concentration of ET-1 raised, compared with the control,when the concentration of ET-1 was at 0.2ug/ml,there was the most obviously promotion of the adhesion and migration(P<0.01). When the concentration of ET-1 was at 2ug/ml,it inhibited the adhesion and migration of A375 human melanoma cells with the concentration of ET-1 raised.3.When the concentration of ET-1 was between 0.002~0.2ug/ml, the expression of ICAM-1 was inhibited,the content of ICAM-1 of A375 human melanoma cells gradually degraded with the concentration of ET-1 raised, compared with the control,when the concentration of ET-1 was at 0.2ug/ml, the content of ICAM-1 was the lowest(P<0.01). When the concentration of ET-1 was at 2ug/ml, the content of ICAM-1 increased.Conclusions:ET-1 may influence the A375 human melanoma cell growth,the adhesion,the migration and the expression of ICAM-1,it provides an experimental evidence of treating vitiligo patients with ET-1. |